| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -27,292 | 180 |
| Stock-based compensation expense | 83,899 | 58,635 |
| Depreciation and amortization | 26,134 | 15,837 |
| Amortization of right-of-use assets | 5,582 | 3,628 |
| Fair value adjustments on contingent consideration | -1,135 | - |
| Asset and lease impairment charges | 814 | 114 |
| Realized loss on marketable securities | 0 | 0 |
| Other | -1,360 | -926 |
| Accounts receivable | -44,546 | -37,917 |
| Other receivables | 52,208 | 68,484 |
| Inventory | -22,371 | -15,084 |
| Prepaid expenses and other current assets | -642 | 741 |
| Other noncurrent assets | -2,290 | -2,439 |
| Accounts payable | 3,292 | 3,488 |
| Accrued compensation and other related benefits | 2,284 | -7,817 |
| Deferred revenue | -648 | -458 |
| Accrued expenses and other current liabilities | -9,939 | -2,891 |
| Operating lease liability | -7,590 | -4,986 |
| Other noncurrent liabilities | 1,321 | 1,040 |
| Net cash provided by operating activities | 95,273 | 52,059 |
| Purchases of intangible assets | 0 | 0 |
| Asset acquisition, net | 8,616 | - |
| Purchases of property and equipment | 4,158 | 3,471 |
| Purchases of marketable securities | 98,859 | 49,361 |
| Proceeds from sales of marketable securities | 0 | 0 |
| Proceeds from maturities of marketable securities | 100,000 | 50,000 |
| Net cash provided by (used in) investing activities | -11,633 | -2,832 |
| Issuance of common stock from exercise of stock options and employee stock purchase plan purchases | 4,561 | 3,944 |
| Net cash provided by financing activities | 4,561 | 3,944 |
| Effect of exchange rates changes on cash, cash equivalents, and restricted cash | 441 | 474 |
| Net increase in cash, cash equivalents, and restricted cash | 88,642 | 53,645 |
| Cash and cash equivalents at beginning of period | 344,067 | - |
| Cash and cash equivalents at end of period | 432,709 | - |
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)